MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London, WC2B 6NH, UK.
Department of Health Sciences, Univeristy of Leicester, University Road, Leicester, LE1 7RH, UK.
Res Synth Methods. 2017 Dec;8(4):451-464. doi: 10.1002/jrsm.1253. Epub 2017 Jul 25.
Network meta-analysis (NMA) combines direct and indirect evidence from trials to calculate and rank treatment estimates. While modelling approaches for continuous and binary outcomes are relatively well developed, less work has been done with time-to-event outcomes. Such outcomes are usually analysed using Cox proportional hazard (PH) models. However, in oncology with longer follow-up time, and time-dependent effects of targeted treatments, this may no longer be appropriate. Network meta-analysis conducted in the Bayesian setting has been increasing in popularity. However, fitting the Cox model is computationally intensive, making it unsuitable for many datasets. Royston-Parmar models are a flexible alternative that can accommodate time-dependent effects. Motivated by individual participant data (IPD) from 37 cervical cancer trials (5922 women) comparing surgery, radiotherapy, and chemotherapy, this paper develops an IPD Royston-Parmar Bayesian NMA model for overall survival. We give WinBUGS code for the model. We show how including a treatment-ln(time) interaction can be used to conduct a global test for PH, illustrate how to test for consistency of direct and indirect evidence, and assess within-design heterogeneity. Our approach provides a computationally practical, flexible Bayesian approach to NMA of IPD survival data, which readily extends to include additional complexities, such as non-PH, increasingly found in oncology trials.
网络荟萃分析(NMA)结合了试验中的直接和间接证据,以计算和排列治疗估计值。虽然连续和二分类结局的建模方法相对完善,但针对生存时间结局的研究较少。此类结局通常使用 Cox 比例风险(PH)模型进行分析。然而,在肿瘤学中,随访时间较长,且靶向治疗的作用随时间变化,这种方法可能不再适用。基于贝叶斯框架的 NMA 越来越受欢迎。然而,Cox 模型的拟合计算量很大,使其不适合许多数据集。Royston-Parmar 模型是一种灵活的替代方法,可以适应随时间变化的效应。受 37 项比较手术、放疗和化疗的宫颈癌试验(5922 名女性)的个体参与者数据(IPD)的启发,本文开发了一个用于总体生存的 IPD Royston-Parmar 贝叶斯 NMA 模型。我们提供了用于该模型的 WinBUGS 代码。我们展示了如何使用治疗-ln(时间)交互来进行 PH 的全局检验,说明了如何检验直接和间接证据的一致性,并评估了设计内异质性。我们的方法为 IPD 生存数据的 NMA 提供了一种计算实用、灵活的贝叶斯方法,它可以很容易地扩展到包括其他复杂性,如非 PH,这些在肿瘤学试验中越来越常见。